Taysha Gene Therapies (TSHA) Gains from Investment Securities (2023 - 2025)
Taysha Gene Therapies (TSHA) reported Gains from Investment Securities of $736000.0 for Q4 2025, up 986.75% on a YoY basis from $67725.1 in Q4 2024, and up 152.05% sequentially from $292000.0 in Q3 2025.
Taysha Gene Therapies (TSHA) Gains from Investment Securities (2023 - 2025) Analysis & Trends
Taysha Gene Therapies (TSHA) has 3 years of Gains from Investment Securities data on file, last reported at $736000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 986.75% year-over-year to $736000.0; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (up 7593.75% YoY), and the FY2025 full-year result was $1.2 million, up 7593.75% from the prior year.
- Gains from Investment Securities advanced to $736000.0 in Q4 2025, from $292000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $736000.0 in Q4 2025 to a low of -$66.0 million in Q4 2023.
- A 3-year average of -$7.2 million and a median of -$75000.0 in 2024 frame the typical range for Gains from Investment Securities.
- Peak annual rise in Gains from Investment Securities reached 986.75% in 2025, while the deepest fall reached 130.27% in 2025.
- Tracing TSHA's Gains from Investment Securities over 3 years: stood at -$66.0 million in 2023, then surged by 99.87% to -$83000.0 in 2024, then soared by 986.75% to $736000.0 in 2025.
- Business Quant data shows TSHA's Gains from Investment Securities at $736000.0 in Q4 2025, $292000.0 in Q3 2025, and $273000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Taysha Gene Therapies | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 736,000.00 |
| Dec 31, 2025 | 736,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Sep 30, 2024 | -75,000.00 |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | -195,000.00 |
| Jun 30, 2024 | -195,000.00 |
| Mar 31, 2024 | 337,000.00 |
| Mar 31, 2024 | 337,000.00 |
| Dec 31, 2023 | -65.96 Mn |
| Dec 31, 2023 | -65.96 Mn |